G
Geert Jan Creemers
Researcher at Radboud University Nijmegen
Publications - 13
Citations - 2440
Geert Jan Creemers is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Bevacizumab & Oxaliplatin. The author has an hindex of 9, co-authored 13 publications receiving 2178 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol,Miriam Koopman,Annemieke Cats,C.J. Rodenburg,Geert Jan Creemers,Jolanda G Schrama,Frans L. G. Erdkamp,A. Vos,Cees J van Groeningen,Harm Sinnige,Dirk J. Richel,Emile E. Voest,Jeroen R. Dijkstra,Marianne E. Vink-Börger,Ninja Antonini,Linda Mol,Johan H. J. M. van Krieken,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life.
Journal ArticleDOI
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Fermé,Houchingue Eghbali,J.H. Meerwaldt,Chantal Rieux,Jacques Bosq,Françoise Berger,Theodore Girinsky,Pauline Brice,Mars B. van't Veer,Jan Walewski,Pierre Lederlin,Umberto Tirelli,Patrice Carde,Eric Van Den Neste,Emmanuel Gyan,Mathieu Monconduit,Marine Diviné,John M. M. Raemaekers,Gilles Salles,Evert M. Noordijk,Geert Jan Creemers,Jean Gabarre,Anton Hagenbeek,Oumedaly Reman,Michel Blanc,José Thomas,B. Vie,Johanna Kluin-Nelemans,Fernando Viseu,Joke W. Baars,Philip Poortmans,Pieternella J. Lugtenburg,Christian Carrie,Jérôme Jaubert,Michel Henry-Amar +34 more
TL;DR: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features and in patients with unfavorable features, four courses of chemotherapyplus involved- field radiotherapy ought to be thestandard treatment.
Journal ArticleDOI
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Linda M. Henricks,Carin A.T.C. Lunenburg,Femke M. de Man,Didier Meulendijks,Geert W.J. Frederix,Emma Kienhuis,Geert Jan Creemers,Arnold Baars,Vincent O. Dezentjé,Alexander L T Imholz,Frank J.F. Jeurissen,Johanna E.A. Portielje,Rob L. H. Jansen,Paul Hamberg,Albert J. ten Tije,Helga J. Droogendijk,Miriam Koopman,Peter Nieboer,Marlène H.W. van de Poel,Caroline M.P.W. Mandigers,Hilde Rosing,Jos H. Beijnen,Jos H. Beijnen,Erik van Werkhoven,André B.P. van Kuilenburg,Ron H.N. van Schaik,Ron H.J. Mathijssen,Jesse J. Swen,Hans Gelderblom,Annemieke Cats,Henk-Jan Guchelaar,Jan H.M. Schellens,Jan H.M. Schellens +32 more
TL;DR: Overall, fluoropyrimidine-related severe toxicity was higher in DPYD variant carriers than in wild-type patients in this prospective, multicentre, safety analysis in 17 hospitals in the Netherlands, and relative risks for severe toxicity were compared between the current study and a historical cohort ofDPYD variant allele carriers treated with full dose fluoropyridine-based therapy.
Journal ArticleDOI
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Jolien Tol,Miriam Koopman,C.J. Rodenburg,Annemieke Cats,Geert Jan Creemers,J. G. Schrama,Frans L. G. Erdkamp,A. Vos,Linda Mol,Ninja Antonini,C.J.A. Punt +10 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible.
Journal ArticleDOI
Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer.
Raphaëla C. Dresen,Marleen J.E.M. Gosens,Hendrik Martijn,Grard A. P. Nieuwenhuijzen,Geert Jan Creemers,Alette W. Daniels-Gooszen,Adriaan J. C. van den Brule,Hetty A. van den Berg,Harm J. T. Rutten +8 more
TL;DR: Neoadjuvant radio (chemo-) therapy is the best option in order to realize a radical resection and re-irradiation is feasible in patients who already received irradiation as part of the primary rectal cancer treatment.